Can a phone app help schizophrenia patients stay on track?
NCT ID NCT04602741
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a smartphone app called A4i designed to help people with schizophrenia manage their illness and stay connected with their care providers. 91 adults with schizophrenia or related disorders used the app for 6 months. The goal was to see if the app was practical and safe to use, not to measure health improvements.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A4i smartphone app (behavioral intervention)
- What this could lead to
- If successful, this could point toward a low-cost digital tool to support schizophrenia self-management and improve communication with healthcare providers.
- What could go wrong
- This was a small feasibility study (91 participants) testing only whether the app is usable and safe, not whether it improves health outcomes. Results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
91 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants will be adults, 18 years of age or older, with a chart diagnosis of a DSM-5 schizophrenia spectrum illness confirmed by a structured diagnostic interview (SCID-5)40. 2. All participants will be engaged in outpatient psychiatric treatment. 3. Proficiency in English. 4. Own and use an Android or iOS smartphone. Exclusion Criteria: 1. Lack of capacity with no identified substitute decision maker. 2. Intellectual disability.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychotic disorders are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6R2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia